Nextcure provides updates on nc318 clinical program

Beltsville, md., dec. 17, 2020 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the clinical trial program for nc318, its first-in-class immunomedicine against siglec15 (s15), a novel immunomodulatory target.
NXTC Ratings Summary
NXTC Quant Ranking